Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Cash from Operations (2017 - 2024)

Solid Biosciences' Cash from Operations history spans 8 years, with the latest figure at 29645000.0 for Q4 2024.

  • For Q4 2024, Cash from Operations fell 42.37% year-over-year to 29645000.0; the TTM value through Dec 2024 reached 100012000.0, down 6.19%, while the annual FY2024 figure was 100012000.0, 6.19% down from the prior year.
  • Cash from Operations for Q4 2024 was 29645000.0 at Solid Biosciences, down from 23708000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1307000.0 in Q4 2020 and bottomed at 34480000.0 in Q4 2022.
  • The 5-year median for Cash from Operations is 21120000.0 (2021), against an average of 21326600.0.
  • The largest annual shift saw Cash from Operations soared 106.15% in 2020 before it tumbled 1697.09% in 2021.
  • A 5-year view of Cash from Operations shows it stood at 1307000.0 in 2020, then crashed by 1697.09% to 20874000.0 in 2021, then crashed by 65.18% to 34480000.0 in 2022, then skyrocketed by 39.61% to 20823000.0 in 2023, then plummeted by 42.37% to 29645000.0 in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Cash from Operations are 29645000.0 (Q4 2024), 23708000.0 (Q3 2024), and 21467000.0 (Q2 2024).